Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2018 Filed Feb 28, 2018 00:30 UTC |
BOURLA ALBERTDirector · Chief Operating Officer
|
Exercise / conversionStock Appreciation Rights · Derivative | 25,387 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004455 · doc4.xml · derivative · entry 5 BOURLA ALBERT · CIK 0001595703 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,387 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:30 UTC |
BOURLA ALBERTDirector · Chief Operating Officer
|
Tax withholdingCommon Stock | 8,100 | $35.98 | $291,438.00 |
DisclosureSEC source: 0001225208-18-004455 · doc4.xml · nonDerivative · entry 3 BOURLA ALBERT · CIK 0001595703 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,197 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:30 UTC |
BOURLA ALBERTDirector · Chief Operating Officer
|
Tax withholdingCommon Stock | 5,873 | $36.26 | $212,954.98 |
DisclosureSEC source: 0001225208-18-004455 · doc4.xml · nonDerivative · entry 2 BOURLA ALBERT · CIK 0001595703 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,297 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:30 UTC |
BOURLA ALBERTDirector · Chief Operating Officer
|
Exercise / conversionCommon Stock | 25,387 | $18.90 | $479,814.30 |
DisclosureSEC source: 0001225208-18-004455 · doc4.xml · nonDerivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:30 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 174,081 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004456 · doc4.xml · derivative · entry 5 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 174,081 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:30 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 55,544 | $35.98 | $1,998,473.12 |
DisclosureSEC source: 0001225208-18-004456 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 401,981 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:30 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 53,945 | $36.26 | $1,956,045.70 |
DisclosureSEC source: 0001225208-18-004456 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 457,525 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:30 UTC |
DAMELIO FRANK AExecutive Vice President
|
Exercise / conversionCommon Stock | 174,081 | $18.90 | $3,290,130.90 |
DisclosureSEC source: 0001225208-18-004456 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:32 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionStock Appreciation Rights · Derivative | 174,081 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004457 · doc4.xml · derivative · entry 6 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 174,081 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:32 UTC |
Dolsten MikaelPresident R&D
|
Tax withholdingCommon Stock | 55,544 | $35.98 | $1,998,473.12 |
DisclosureSEC source: 0001225208-18-004457 · doc4.xml · nonDerivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,772 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:32 UTC |
Dolsten MikaelPresident R&D
|
Tax withholdingCommon Stock | 53,949 | $36.26 | $1,956,190.74 |
DisclosureSEC source: 0001225208-18-004457 · doc4.xml · nonDerivative · entry 2 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,316 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:32 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionCommon Stock | 174,081 | $18.90 | $3,290,130.90 |
DisclosureSEC source: 0001225208-18-004457 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:38 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 15,957 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004459 · doc4.xml · derivative · entry 6 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,957 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:38 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
Tax withholdingCommon Stock | 5,091 | $35.98 | $183,174.18 |
DisclosureSEC source: 0001225208-18-004459 · doc4.xml · nonDerivative · entry 3 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,176 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:38 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
Tax withholdingCommon Stock | 3,692 | $36.26 | $133,871.92 |
DisclosureSEC source: 0001225208-18-004459 · doc4.xml · nonDerivative · entry 2 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,267 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:38 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
Exercise / conversionCommon Stock | 15,957 | $18.90 | $301,587.30 |
DisclosureSEC source: 0001225208-18-004459 · doc4.xml · nonDerivative · entry 1 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:38 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 39,555 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004460 · doc4.xml · derivative · entry 6 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 39,555 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F7 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:38 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Tax withholdingCommon Stock | 12,621 | $35.98 | $454,103.58 |
DisclosureSEC source: 0001225208-18-004460 · doc4.xml · nonDerivative · entry 3 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,269 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:38 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Tax withholdingCommon Stock | 11,262 | $36.26 | $408,360.12 |
DisclosureSEC source: 0001225208-18-004460 · doc4.xml · nonDerivative · entry 2 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,890 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:38 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
Exercise / conversionCommon Stock | 39,555 | $18.90 | $747,589.50 |
DisclosureSEC source: 0001225208-18-004460 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:38 UTC |
HILL CHARLES HExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 65,280 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004461 · doc4.xml · derivative · entry 5 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,280 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:38 UTC |
HILL CHARLES HExecutive Vice President
|
Tax withholdingCommon Stock | 20,829 | $35.98 | $749,427.42 |
DisclosureSEC source: 0001225208-18-004461 · doc4.xml · nonDerivative · entry 3 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,106 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:38 UTC |
HILL CHARLES HExecutive Vice President
|
Tax withholdingCommon Stock | 17,674 | $36.26 | $640,859.24 |
DisclosureSEC source: 0001225208-18-004461 · doc4.xml · nonDerivative · entry 2 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,935 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:38 UTC |
HILL CHARLES HExecutive Vice President
|
Exercise / conversionCommon Stock | 65,280 | $18.90 | $1,233,792.00 |
DisclosureSEC source: 0001225208-18-004461 · doc4.xml · nonDerivative · entry 1 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:43 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 15,885 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004462 · doc4.xml · derivative · entry 5 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,885 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:43 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 5,068 | $35.98 | $182,346.64 |
DisclosureSEC source: 0001225208-18-004462 · doc4.xml · nonDerivative · entry 3 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,100 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:43 UTC |
JOHNSON RADY AExecutive Vice President
|
Tax withholdingCommon Stock | 3,680 | $36.26 | $133,436.80 |
DisclosureSEC source: 0001225208-18-004462 · doc4.xml · nonDerivative · entry 2 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,168 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:43 UTC |
JOHNSON RADY AExecutive Vice President
|
Exercise / conversionCommon Stock | 15,885 | $18.90 | $300,226.50 |
DisclosureSEC source: 0001225208-18-004462 · doc4.xml · nonDerivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:43 UTC |
Lewis-Hall Freda CExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 91,876 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004464 · doc4.xml · derivative · entry 5 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 91,876 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:43 UTC |
Lewis-Hall Freda CExecutive Vice President
|
Tax withholdingCommon Stock | 29,315 | $35.98 | $1,054,753.70 |
DisclosureSEC source: 0001225208-18-004464 · doc4.xml · nonDerivative · entry 3 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,629 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:43 UTC |
Lewis-Hall Freda CExecutive Vice President
|
Tax withholdingCommon Stock | 26,555 | $36.26 | $962,884.30 |
DisclosureSEC source: 0001225208-18-004464 · doc4.xml · nonDerivative · entry 2 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,944 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:43 UTC |
Lewis-Hall Freda CExecutive Vice President
|
Exercise / conversionCommon Stock | 91,876 | $18.90 | $1,736,456.40 |
DisclosureSEC source: 0001225208-18-004464 · doc4.xml · nonDerivative · entry 1 Lewis-Hall Freda C · CIK 0001437909 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:43 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 28,288 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004463 · doc4.xml · derivative · entry 5 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,288 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:43 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 9,026 | $35.98 | $324,755.48 |
DisclosureSEC source: 0001225208-18-004463 · doc4.xml · nonDerivative · entry 3 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,514 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:43 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 6,541 | $36.26 | $237,176.66 |
DisclosureSEC source: 0001225208-18-004463 · doc4.xml · nonDerivative · entry 2 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,540 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:43 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Exercise / conversionCommon Stock | 28,288 | $18.90 | $534,643.20 |
DisclosureSEC source: 0001225208-18-004463 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:51 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 91,876 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004472 · doc4.xml · derivative · entry 5 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 91,876 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:51 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 29,315 | $35.98 | $1,054,753.70 |
DisclosureSEC source: 0001225208-18-004472 · doc4.xml · nonDerivative · entry 3 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,463 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:51 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 29,194 | $36.26 | $1,058,574.44 |
DisclosureSEC source: 0001225208-18-004472 · doc4.xml · nonDerivative · entry 2 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,778 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:51 UTC |
SUSMAN SALLYExecutive Vice President
|
Exercise / conversionCommon Stock | 91,876 | $18.90 | $1,736,456.40 |
DisclosureSEC source: 0001225208-18-004472 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:53 UTC |
OLSON LAURIE JExecutive Vice President
|
Exercise / conversionStock Appreciation Rights · Derivative | 15,716 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004475 · doc4.xml · derivative · entry 5 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,716 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:53 UTC |
OLSON LAURIE JExecutive Vice President
|
Tax withholdingCommon Stock | 5,015 | $35.98 | $180,439.70 |
DisclosureSEC source: 0001225208-18-004475 · doc4.xml · nonDerivative · entry 3 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,558 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:53 UTC |
OLSON LAURIE JExecutive Vice President
|
Tax withholdingCommon Stock | 3,649 | $36.26 | $132,312.74 |
DisclosureSEC source: 0001225208-18-004475 · doc4.xml · nonDerivative · entry 2 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,573 F2 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F3 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 00:53 UTC |
OLSON LAURIE JExecutive Vice President
|
Exercise / conversionCommon Stock | 15,716 | $18.90 | $297,032.40 |
DisclosureSEC source: 0001225208-18-004475 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon). Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 01:58 UTC |
READ IAN CDirector · Chairman & CEO
|
Exercise / conversionStock Appreciation Rights · Derivative | 483,559 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004488 · doc4.xml · derivative · entry 9 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 483,559 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 01:58 UTC |
READ IAN CDirector · Chairman & CEO
|
Exercise / conversionStock Appreciation Rights · Derivative | 420,000 | $0.00 Strike: $20.90 | $0.00 |
DisclosureSEC source: 0001225208-18-004488 · doc4.xml · derivative · entry 8 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 420,000 shares Expires 2018-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 01:58 UTC |
READ IAN CDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 157,353 | $35.98 | $5,661,560.94 |
DisclosureSEC source: 0001225208-18-004488 · doc4.xml · nonDerivative · entry 6 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968,301 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 01:58 UTC |
READ IAN CDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 154,289 | $35.98 | $5,551,318.22 |
DisclosureSEC source: 0001225208-18-004488 · doc4.xml · nonDerivative · entry 5 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,125,654 F4 · shares: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon). F5 · price: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used. Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 01:58 UTC |
READ IAN CDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 154,058 | $36.26 | $5,586,143.08 |
DisclosureSEC source: 0001225208-18-004488 · doc4.xml · nonDerivative · entry 4 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,279,943 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights. F2 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
| February 24, 2018 Filed Feb 28, 2018 01:58 UTC |
READ IAN CDirector · Chairman & CEO
|
Tax withholdingCommon Stock | 126,006 | $36.26 | $4,568,977.56 |
DisclosureSEC source: 0001225208-18-004488 · doc4.xml · nonDerivative · entry 3 READ IAN C · CIK 0001372915 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,434,001 F2 · price: Price is the closing price of Pfizer common stock on February 23, 2018 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.